Navigation Links
Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009
Date:2/24/2010

tempered by the full impact of the third quarter price increase.
  • Nascobal® B12 Nasal Spray:  Net sales were $4.2 million for the three months ended December 31, 2009, compared to $3.8 million in the third quarter.  The increase is due to an increase in prescription volume and market share.

Total net revenues for the three months ended December 31, 2009, were $290.3 million, up $129.0 million, or nearly 80%, from the year ago period, principally driven by limited competition in metoprolol succinate, sumatriptan succinate, meclizine, and dronabinol, as well as the launches of nateglinide and clonidine in the third quarter, and tramadol ER in the fourth quarter 2009.

Gross margin for the fourth quarter 2009 was $91.3 million, or 31.5% of total revenue, an increase of $40.9 million from the comparable period in 2008.  Total generic gross
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related medicine technology :

1. Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results
2. Poniard Pharmaceuticals Secures $20 Million Committed Equity Financing Facility
3. Jazz Pharmaceuticals to Announce Fourth Quarter and Full Year 2009 Financial Results on March 3, 2010
4. QRxPharma Limited and China Aoxing Pharmaceutical Company Announce Strategic Alliance for Development of MoxDuo(R)IV
5. Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010
6. Innovative University of Cincinnati Program Trains Next Generation of Pharmaceutical Professionals
7. Jiangbo Pharmaceuticals Announces Conference Call to Discuss Results for Its Second Quarter of Fiscal Year 2010
8. Adamas Pharmaceuticals Announces In Vitro Data Demonstrating TCAD Therapy is More Potent Than Double Combinations or Monotherapy Against Drug-Resistant Flu Strains
9. Ritter Pharmaceuticals Joins NIH Conference Discussions on Lactose Intolerance and Associated Health Risks
10. Endo Pharmaceuticals Reports Strong Fourth Quarter and Full-Year 2009 Financial Results: Provides 2010 Financial Guidance
11. Alexza Pharmaceuticals Promotes Mark K. Oki to Vice President, Finance and Controller
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... DUBLIN , Jan. 23, 2015  Mallinckrodt plc (NYSE: ... of Directors has approved a share repurchase program. The ... $300 million of Mallinckrodt plc ordinary shares. ... opportunities remain top priorities as we continue to pursue ...
(Date:1/23/2015)... BOSTON , January 23, 2015 ... company, is delighted to announce that the Malcolm Campbell ... Miles Congreve (Vice President of Chemistry), Fiona Marshall ... (Chief Executive Officer and co-founder) for the seminal contributions ...
(Date:1/22/2015)... CLEVELAND , Jan. 22, 2015  ViewRay™, a privately ... entered into an exclusive distributor agreement with ITOCHU Corporation ... radiation therapy system for the treatment of cancer in ... (me-rid-i-an) system, is the world,s first and only MRI-guided ...
Breaking Medicine Technology:Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2
... Texas, April 27, 2012  MetaStat, Inc. (OTCBB: MTST) ... license agreements to patent applications and technology from ... University. The first license agreement covers U.S. Patent ... Screening Test for Anti-Metastasis Treatment Efficacy"; inventors: Jeffrey ...
... 2012 /PRNewswire-iReach/ -- SolutionStart, Corp., a leading ... is proud to announce John Karagiannis as its new ... SolutionStart with over 12-years of strong experience in Information ... Technical Advisor, Designer, and Analyst providing comprehensive technical and ...
Cached Medicine Technology:MetaStat, Inc. Executes Two New Licenses 2MetaStat, Inc. Executes Two New Licenses 3
(Date:1/22/2015)... 2015 AngelWeddingDress, the premier women’s dress ... wedding dresses. View website of AngelWeddingDress.com to ... maternity wedding dresses online for a bridal party. AngelWeddingDress ... quality for them. Its maternity wedding dresses are specially ...
(Date:1/22/2015)... Autocarinsurancebest.com has released a new blog post explaining ... policy . , Auto insurance quotes help many drivers ... longer necessary to call an agent or visit an agency ... a single website: http://autocarinsurancebest.com/ . , Every business who ...
(Date:1/22/2015)... 2015 Yesterday, Senator Holly Mitchell ... Kristin Olsen (R-Modesto) were honored by the California ... biotechnology, biomedical science, medical device and pharmaceutical innovation ... the “2014 Life Sciences Champion” award from CHI ...
(Date:1/22/2015)... January 22, 2015 EBSCO Information Services ... are expanding their relationship in an effort to further promote ... world. While EBSCO has long made AMA journals available via ... agent for The JAMA Network. , Long known ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Step into ... at the Science Museum of Virginia. Wicked Plants, the ... Wicked Plants unearths 75 poisonous, carnivorous and diabolical plants ... each room to uncover the biochemical, physical and neurological ...
Breaking Medicine News(10 mins):Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Wicked Plants are taking over the Science Museum of Virginia 2
... , , , DETROIT, Aug. ... injuries and illnesses, but given the abuse potential many wind up getting hooked ... This was the topic of an interview that aired today on the Rick ... Rampant was the title of the interview and it featured Narconon ...
... TSX: COM, , , VANCOUVER and DEERFIELD, ... CRME/TSX: COM) and its co-development partner Astellas Pharma US, ... single confirmatory additional Phase 3 clinical trial of KYNAPID(TM) ... to sinus rhythm. The trial, to be called ACT ...
... , , , ... , BOSTON, Aug. 10 PAREXEL International Corporation (Nasdaq: ... Fiscal Year ended June 30, 2009. The Company has determined the ... as described in greater detail below. These changes relate to (1) ...
... N.J., Aug. 10 Pharmasset, Inc. (Nasdaq: VRUS ), ... novel drugs to treat viral infections, today reported financial results and ... , , Financial Results , ... June 30, 2009 compared to $0.5 million for the quarter ended ...
... , , Increased caseloads, ... concerns , , WASHINGTON, Aug. 10 ... approximately 4,000 HIV-treating clinicians in the United States [out of a ... survey indicating that while supportive of ongoing health care reform efforts, ...
... , , , ... launch of its national awareness campaign, Cities Go Blue for Colon Cancer ... events kicking off on September 26-27, 2009. , , ... Cancer campaign is to promote awareness about colorectal cancer, by encouraging people ...
Cached Medicine News:Health News:Narconon Graduate Lives to Tell Story of Addiction 2Health News:Additional Clinical Trial to be Conducted for KYNAPID Under FDA Special Protocol Agreement 2Health News:Additional Clinical Trial to be Conducted for KYNAPID Under FDA Special Protocol Agreement 3Health News:Additional Clinical Trial to be Conducted for KYNAPID Under FDA Special Protocol Agreement 4Health News:Additional Clinical Trial to be Conducted for KYNAPID Under FDA Special Protocol Agreement 5Health News:Additional Clinical Trial to be Conducted for KYNAPID Under FDA Special Protocol Agreement 6Health News:PAREXEL International Reports Fourth Quarter and Fiscal Year 2009 Results 2Health News:PAREXEL International Reports Fourth Quarter and Fiscal Year 2009 Results 3Health News:PAREXEL International Reports Fourth Quarter and Fiscal Year 2009 Results 4Health News:PAREXEL International Reports Fourth Quarter and Fiscal Year 2009 Results 5Health News:PAREXEL International Reports Fourth Quarter and Fiscal Year 2009 Results 6Health News:PAREXEL International Reports Fourth Quarter and Fiscal Year 2009 Results 7Health News:PAREXEL International Reports Fourth Quarter and Fiscal Year 2009 Results 8Health News:PAREXEL International Reports Fourth Quarter and Fiscal Year 2009 Results 9Health News:PAREXEL International Reports Fourth Quarter and Fiscal Year 2009 Results 10Health News:PAREXEL International Reports Fourth Quarter and Fiscal Year 2009 Results 11Health News:PAREXEL International Reports Fourth Quarter and Fiscal Year 2009 Results 12Health News:PAREXEL International Reports Fourth Quarter and Fiscal Year 2009 Results 13Health News:PAREXEL International Reports Fourth Quarter and Fiscal Year 2009 Results 14Health News:PAREXEL International Reports Fourth Quarter and Fiscal Year 2009 Results 15Health News:PAREXEL International Reports Fourth Quarter and Fiscal Year 2009 Results 16Health News:PAREXEL International Reports Fourth Quarter and Fiscal Year 2009 Results 17Health News:Pharmasset Reports Fiscal Third Quarter 2009 Financial Results 2Health News:Pharmasset Reports Fiscal Third Quarter 2009 Financial Results 3Health News:Pharmasset Reports Fiscal Third Quarter 2009 Financial Results 4Health News:Pharmasset Reports Fiscal Third Quarter 2009 Financial Results 5Health News:Pharmasset Reports Fiscal Third Quarter 2009 Financial Results 6Health News:Pharmasset Reports Fiscal Third Quarter 2009 Financial Results 7Health News:Pharmasset Reports Fiscal Third Quarter 2009 Financial Results 8Health News:HIV-Treating Clinicians Support Health Care Reform, Express Caution 2Health News:HIV-Treating Clinicians Support Health Care Reform, Express Caution 3Health News:HIV-Treating Clinicians Support Health Care Reform, Express Caution 4Health News:HIV-Treating Clinicians Support Health Care Reform, Express Caution 5Health News:Cities Go Blue for Colon Cancer 2
Superior Skin Care...FlexWear skin barrier provides skin protection for an extended wear time....
Firstchoice drainable pouch with softflex skin barrier, cushionfit backing, transparent odor-barrier quiet film and microporous adhesive....
Inquire...
... Protects the skin over extended wearing ... barrier is the barrier of choice ... added benefit of it being discreet ... Security and confidence assured with internal ...
Medicine Products: